Promising early reports of the effect of CPIs targeting PD-1 in HCC with manageable toxicity paved the way for several large studies of CPIs alone or in combination with other drugs, including randomized clinical trials. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.